Journey Medical Corporation (DERM) Research
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Market snapshot
- Symbol
- DERM
- Price
- $6.22
- Day change
- +5.07%
- Market cap
- $171.2M
- P/E ratio
- -17.71x
- 52-week range
- 4.31-9.555
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Next earnings
- in 2 months
- Analyst price target
- $11.75
Peer companies
Recent insider activity
- Alloush Ramsey — A-Award (46863 shares) on 2026-04-22
- Alloush Ramsey — A-Award (62795 shares) on 2026-04-22
- Benesch Joseph — A-Award (28907 shares) on 2026-04-22
- Benesch Joseph — A-Award (41860 shares) on 2026-04-22
- Maraoui Claude — A-Award (49277 shares) on 2026-04-22
Open Journey Medical Corporation (DERM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.